ZS Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company's zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. The Company has completed Phase III development of its product candidate, sodium zirconium cyclosilicate (ZS-9), for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed three clinical studies with ZS-9 for patients with hyperkalemia, including patients with chronic kidney disease (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS) inhibitor therapy.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ZSPH
- CUSIP: N/A
- Web: www.zspharma.com
- 50 Day Moving Avg: $85.57
- 200 Day Moving Avg: $66.48
- 52 Week Range: $37.52 - $91.24
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.71
- P/E Growth: 0.00
- Return on Equity: -66.24%
- Return on Assets: -58.88%
- Average Volume: 918,928 shs.
Frequently Asked Questions for ZS Pharma (NASDAQ:ZSPH)
What is ZS Pharma's stock symbol?
ZS Pharma trades on the NASDAQ under the ticker symbol "ZSPH."
How were ZS Pharma's earnings last quarter?
ZS Pharma Inc (NASDAQ:ZSPH) announced its quarterly earnings data on Monday, November, 9th. The company reported ($0.41) EPS for the quarter, topping the Zacks' consensus estimate of ($1.04) by $0.63. View ZS Pharma's Earnings History.
Who are some of ZS Pharma's key competitors?
Some companies that are related to ZS Pharma include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE) and Agios Pharmaceuticals (AGIO).
How do I buy ZS Pharma stock?
Shares of ZS Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZS Pharma's stock price today?
MarketBeat Community Rating for ZS Pharma (NASDAQ ZSPH)MarketBeat's community ratings are surveys of what our community members think about ZS Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ZS Pharma stock can currently be purchased for approximately $89.98.
Earnings History for ZS Pharma (NASDAQ:ZSPH)Earnings History by Quarter for ZS Pharma (NASDAQ ZSPH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for ZS Pharma (NASDAQ:ZSPH)
Current Year EPS Consensus Estimate: $-4.68 EPS
Next Year EPS Consensus Estimate: $-5.08 EPS
Dividend History for ZS Pharma (NASDAQ:ZSPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ZS Pharma (NASDAQ:ZSPH)Insider Trades by Quarter for ZS Pharma (NASDAQ:ZSPH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/21/2015||Todd A. Creech||CFO||Sell||70,000||$49.84||$3,488,800.00|| |
|6/8/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||175,427||$57.86||$10,150,206.22|| |
|6/4/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||111,597||$57.30||$6,394,508.10|| |
|6/2/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||296,423||$58.00||$17,192,534.00|| |
|6/23/2014||A/S Novo||Insider||Buy||275,000||$18.00||$4,950,000.00|| |
|6/23/2014||Guy P Nohra||Director||Buy||200,000||$18.00||$3,600,000.00|| |
|6/23/2014||Park Bioventures Lp Devon||Major Shareholder||Buy||160,000||$18.00||$2,880,000.00|| |
Headline Trends for ZS Pharma (NASDAQ:ZSPH)
Latest Headlines for ZS Pharma (NASDAQ:ZSPH)
ZS Pharma (ZSPH) Chart for Wednesday, July, 26, 2017